Sunday, October 4, 2009

>TOP PICKS (SHAREKHAN)

The market mood remained upbeat during September 2009 on sustained buying interest from domestic as well as foreign institutions amidst good liquidity flow. This was despite rising discomfort on valuations. During the month, the Sensex and Nifty gained 9.2% and 8.6% respectively and our portfolio of top picks performed much in line with these indices delivering returns of 8.2%. Two additions made to the portfolio of top picks in September 2009—IDBI Bank and IPCA Laboratories—proved to be portfolio out performers rising by handsome 17.5% and 14.4% respectively.

For October 2009, we are making two changes to the basket of top picks. We are replacing Bajaj Holdings and Investment, which ran up by sharp 14.3% in September, with UltraTech Cement. We believe, UltraTech Cement would attract substantial buying on the proposed merger of Grasim Industries’ cement business with UltraTech Cement. We are also replacing Emco Transformers with Torrent Pharmaceuticals, which is trading cheap on valuations despite strong growth prospects and expectations of good results for the quarter ended September 2009.

  • Apollo Tyres
  • Bharti Airtel
  • Bharat Heavy Electricals
  • Godrej Consumer
  • IDBI Bank Ltd.
  • IPCA Lab
  • ITC
  • Reliance Industries
  • Torrent Pharma
  • Ultra Tech Cement
To see full report: TOP PICKS

>BIOCON LIMITED (MERRILL LYNCH)

Poised for re-rating; PO raised

Earnings upgrade, likely re-rating
We raise PO to Rs341 (earlier Rs165) based on (1) upgrade in EPS forecasts by 25-28% over FY10-11, following improved sales visibility in bio-pharma and customs research, as well as milestone receipts, and (2) expected re-rating to 18x FY11E EPS (earlier 11x) on growth ahead of peers as well as past averages, and potential triggers of further outsourcing deals.

Stronger traction in biopharma and custom research
We expect insulin and immunosuppressant i.e. biopharma, which represents ~34% of sales, to grow at 25-32% over next 2 years (compared to earlier 22-25%) driven by new launches in RoW and EU markets. We similarly expect Custom research (~15%) to register 34% CAGR compared to earlier 27% CAGR, on faster scale-up of BMS contract, from 260 to 400 scientists. Outlook for residual domestic formulations and statins business is stable in line with our expectations.

Upside risk to our forecasts
We see upside risk from (1) technology income from recently concluded deal with Mylan on biogenerics research, which may be as high as US$20mn vs our peak assumption of US$10mn for FY11 (12% of EPS), and (2) outlicensing for oral insulin (IN-105, Phase III) which may have upfront receipts upto $30mn.

Valuations attractive, upside triggers ahead
Stock trades at 13.7x 1-yr forward P/E, which is 10% disc to historical average. We expect stock to re-rate given (1) improved growth visibility, (2) expectation of upsides from Mylan deal & out-licensing deal (IN-105).

To see full report: BIOCON LIMITED

>ASIAN PAINTS (KOTAK SECURITIES)

Sitting pretty.

Asian Paints (APNT) continues to be our top pick in midcap FMCG as we
see (1) good volume growth sustaining, (2) potential for positive margin surprise in FY2010E versus Street estimates and (3) likely pickup in residential sales volumes in FY2010-11E. Our EPS estimates are the highest on the Street and 10% higher than consensus. Reiterate ADD.

Sustaining good volume growth
In our view, factors aiding the good volume growth in decoratives (likely >12% in 1QFY10, similar trends seen in 2QFY10E) for APNT are (1) continuing good demand conditions in Tier II and III towns, (2) shorter repainting cycle driven by likely improvement in penetration and (3) likely return of demand in key metros. Media reports suggest APNT’s sales growth in Tier II, III towns are outperforming top metros—confirming the view highlighted earlier (report titled “Bright prospects” dated July 27, 2009). The company is likely deriving ~65% of revenues from these markets.

Mix improvement and input cost correction pose upside risks to our (relatively high) estimates
We believe that upside risk to our aggressive EBITDA margin assumption of 17.5% for FY2010E
exist as there is opportunity for APNT to retain significant portion of input cost correction in
FY2010E as the competition is rational and price differentiation is not a critical decision making
factor for the consumer (in higher end products, particularly emulsions). We highlight that our EPS estimates are highest on the Street, Rs60 and Rs69.8 (standalone) for FY2010E and FY2011E, respectively (Street estimates are Rs56.7 and Rs66.7 (consolidated)).

While APNT prefers volume growth over pricing led growth, we believe that, (1) relatively stronger position in emulsions, (2) underlying mix improvement and (3) benefits of input cost correction have helped EBITDA margins expansion of 650 bps to 21% in 1QFY10. We note that 1QFY10 margin performance is probably an outlier as (1) the company has effected a ~2.5% weighted average price correction in July 2009 and (2) 1QFY10 likely had the highest benefits of input cost correction (particularly MTO).

Favorable structural growth drivers
Growth drivers over the medium term, in our view, are, (1) growth in number of tinting machines = growth in emulsions, (2) upside in residential demand, (3) strong performance in South India and (4) improvement in mix.

  • Growth in tinting machines implies a corresponding growth in emulsions. APNT has a reach of ~26,000 distributors, we believe that further upsides from mix improvement is likely over the next 3-4 years as the company’s plans to continue adding 1,000 TMs every year. At present, APNT has about 13,000 tinting machines (TM) installed, and it was adding about 1,000 TMs annually over the last 4-5 years. We believe that the addition of TM has a direct correlation to emulsions growth which APNT had over the last few years.
  • Upswing in residential demand. APNT derives about 10 % of paints volume from new construction and the rest from repainting activity. Likely upswing in residential demand in FY2010E after the slump in FY2009 augurs well for APNT. KIE’s real estate analysts, Puneet Jain and Sandeep Reddy, expect a strong pick up in residential sales volumes in FY2010E and FY2011E.

To see full report: ASIAN PAINTS

>ING VYSYA BANK (INDIA INFOLINE)

ING Vysya Bank with an asset base of Rs318 bn is the sixth largest bank in the private banking space. The bank had a market share of mere 3% in loans and ~3.5% in deposits among private banks at end FY09. IVB is gearing up for brisk growth by aggressively expanding its presence outside South India, its traditional stronghold market. The recent capital infusion of Rs4.15bn would support this initiative. At CMP Rs 270, the stock trading is 1.4x FY11 P/BV based on consensus estimates.

  • Loan growth to revive in H2 FY10
  • Aiming at pan-India presence
  • NIM ti improve with decrease in cost-of-deposits
  • Raised capital at relatively cheap valuations
To see full report: ING VYSYA BANK